DBV Tech And Nestlé Health Science Form Collaboration To Develop And Commercialize A Novel Diagnostic Test For Pediatric Milk Allergy
Collaboration will support DBV’s Mission to Develop Transformational Product Candidates for the Care of Pediatric Patients Suffering from Food Allergies
Under the Terms of the Agreement, DBV will Develop a Ready-To-Use Test to Diagnose Allergy to Cow’s Milk Protein
DBV is Eligible to Receive up to €100 Million in Potential Development, Registration and Commercial Milestones, while Granting Global Commercialization Rights to Nestlé Heath Science
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that it has entered into an exclusive global collaboration with Nestlé Health Science for the development and, if approved, commercialization of MAG1C, an innovative, ready-to-use and standardized atopy patch-test for the diagnosis of Cow’s Milk allergy (CMPA) in infants and toddlers.
By leveraging its proprietary Viaskin® technology platform, DBV will be responsible for developing this new pharmaceutical product candidate, and if approved by the appropriate regulatory agencies, Nestlé Health Science will support its worldwide commercialization through its range of nutritional solutions tailor-made for babies and young children suffering from CMPA and other food allergies and intolerances.
DBV Technologies’ Chairman and Chief Executive Officer, Dr. Pierre-Henri Benhamou, said, “Improving the lives of those suffering from food allergies is DBV’s mission, and through this exciting partnership with Nestlé Health Science, we are further extending our portfolio of potentially transformational and cutting-edge products. Combining DBV’s innovative and proprietary technology with Nestlé Health Science’s global presence and expertise in nutritional therapies is a synergistic approach that we believe has the potential to improve the overall health of our patients.”
Greg Behar, CEO of Nestlé Health Science, said, “This innovation can become the breakthrough diagnostic for CMPA. Early diagnosis and nutritional intervention helps get infants happily back on the path of healthy development, alleviate the anxieties of parents and reduce healthcare costs. Our reach in the field of pediatric allergy makes Nestlé Health Science an ideal commercialization partner for DVB’s innovative diagnostic patch. This collaboration is another step in our strategy of advancing the role of nutrition through science-based innovation.”
Under the terms of the agreement, DBV will be eligible to receive up to €100 million in development, registration and commercial milestones, including an upfront payment of €10 million. DBV will be responsible for performing development activities up through a pivotal Phase III clinical program, following which Nestlé Health Science has the exclusive right to commercialize the product globally, if approved. DBV will pay for all development-related costs of MAG1C, including a worldwide clinical program, as well as manufacturing costs. If MAG1C is successfully manufactured by DBV, the company will receive a supply price with a mark-up from Nestlé Health Science. In addition, Nestlé Health Science will pay to DBV tiered royalties on global product sales. This new diagnostic test is expected to be submitted for approval to regulatory authorities worldwide by 2021.
CMPA is a difficult to diagnose condition that impacts up to 2-3%1 of infants and toddlers aged two and under during a critical stage of their development. Amongst its range of nutritional therapies across a broad spectrum of health conditions and ages, Nestlé Health Science already has a range of nutritional solutions tailor-made for babies and young children with cow’s milk protein allergy and other food allergies/intolerances (Althéra®, Alfaré®, Alfamino®).
About DBV Technologies
DBV Technologies developed Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self- administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
About Nestlé Health Science
Nestlé Health Science, a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and our partners in healthcare. Its portfolio of nutrition solutions, diagnostics, devices and drugs, targets a number of heath areas, such as inborn errors of metabolism, pediatric and acute care, obesity care, healthy aging as well as gastrointestinal and brain health. Through investing in innovation and leveraging leading edge science, we bring forward innovative nutritional therapies with proven clinical, health economic value and quality of life benefits. Nestlé Health Science employs around 3,000 people worldwide and is headquartered in Epalinges (near Lausanne), Switzerland. For more information, please visit: www.nestlehealthscience.com.
Under the Terms of the Agreement, DBV will Develop a Ready-To-Use Test to Diagnose Allergy to Cow’s Milk Protein
DBV is Eligible to Receive up to €100 Million in Potential Development, Registration and Commercial Milestones, while Granting Global Commercialization Rights to Nestlé Heath Science
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that it has entered into an exclusive global collaboration with Nestlé Health Science for the development and, if approved, commercialization of MAG1C, an innovative, ready-to-use and standardized atopy patch-test for the diagnosis of Cow’s Milk allergy (CMPA) in infants and toddlers.
By leveraging its proprietary Viaskin® technology platform, DBV will be responsible for developing this new pharmaceutical product candidate, and if approved by the appropriate regulatory agencies, Nestlé Health Science will support its worldwide commercialization through its range of nutritional solutions tailor-made for babies and young children suffering from CMPA and other food allergies and intolerances.
DBV Technologies’ Chairman and Chief Executive Officer, Dr. Pierre-Henri Benhamou, said, “Improving the lives of those suffering from food allergies is DBV’s mission, and through this exciting partnership with Nestlé Health Science, we are further extending our portfolio of potentially transformational and cutting-edge products. Combining DBV’s innovative and proprietary technology with Nestlé Health Science’s global presence and expertise in nutritional therapies is a synergistic approach that we believe has the potential to improve the overall health of our patients.”
Greg Behar, CEO of Nestlé Health Science, said, “This innovation can become the breakthrough diagnostic for CMPA. Early diagnosis and nutritional intervention helps get infants happily back on the path of healthy development, alleviate the anxieties of parents and reduce healthcare costs. Our reach in the field of pediatric allergy makes Nestlé Health Science an ideal commercialization partner for DVB’s innovative diagnostic patch. This collaboration is another step in our strategy of advancing the role of nutrition through science-based innovation.”
Under the terms of the agreement, DBV will be eligible to receive up to €100 million in development, registration and commercial milestones, including an upfront payment of €10 million. DBV will be responsible for performing development activities up through a pivotal Phase III clinical program, following which Nestlé Health Science has the exclusive right to commercialize the product globally, if approved. DBV will pay for all development-related costs of MAG1C, including a worldwide clinical program, as well as manufacturing costs. If MAG1C is successfully manufactured by DBV, the company will receive a supply price with a mark-up from Nestlé Health Science. In addition, Nestlé Health Science will pay to DBV tiered royalties on global product sales. This new diagnostic test is expected to be submitted for approval to regulatory authorities worldwide by 2021.
CMPA is a difficult to diagnose condition that impacts up to 2-3%1 of infants and toddlers aged two and under during a critical stage of their development. Amongst its range of nutritional therapies across a broad spectrum of health conditions and ages, Nestlé Health Science already has a range of nutritional solutions tailor-made for babies and young children with cow’s milk protein allergy and other food allergies/intolerances (Althéra®, Alfaré®, Alfamino®).
About DBV Technologies
DBV Technologies developed Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self- administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
About Nestlé Health Science
Nestlé Health Science, a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and our partners in healthcare. Its portfolio of nutrition solutions, diagnostics, devices and drugs, targets a number of heath areas, such as inborn errors of metabolism, pediatric and acute care, obesity care, healthy aging as well as gastrointestinal and brain health. Through investing in innovation and leveraging leading edge science, we bring forward innovative nutritional therapies with proven clinical, health economic value and quality of life benefits. Nestlé Health Science employs around 3,000 people worldwide and is headquartered in Epalinges (near Lausanne), Switzerland. For more information, please visit: www.nestlehealthscience.com.